Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + FLOT in Resectable Gastric Cancer
NCT04354662Phase 2Completed
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2020
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: Pathological complete response rate at 6 months and 3-year Disease-Free Survival Rate. Started May 2020; status: completed.
02
Drugs
toripalimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04354662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04354662.